The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan: First Approval
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Ogitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 352
Shitara, K., Iwata, H., Takahashi, S., Tamura, K., Park, H., Modi, S., Tsurutani, J., Kadowaki, S., Yamaguchi, K., Iwasa, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30088-9 · Cited by 232
Takegawa, N., Nonagase, Y., Yonesaka, K., Sakai, K., Maenishi, O., Ogitani, Y., Tamura, T., Nishio, K., Nakagawa, K., & Tsurutani, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30870 · Cited by 196
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32408 · Cited by 92
Tsurutani, J., Park, H., Doi, T., Modi, S., Takahashi, S., Nakagawa, K., Krop, I. E., Waqar, S. N., Yoh, K., Li, B., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.244 · Cited by 27
Modi, S., Tsurutani, J., Tamura, K., Park, H., Sagara, Y., Murthy, R., Iwata, H., Krop, I. E., Doi, T., Redfern, C., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p6-17-02 · Cited by 27
Cited by
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 274
Metadata
- Authors
- Keam, S. J.
- Venue
- Drugs
- Published
- 2020-03-07
- Volume
- 80
- Issue
- 5
- Pages
- 501-508
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3009885756
- Cited by
- 270
- References
- 11
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab Deruxtecan: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01281-4
- The paper
- Keam, S. J. (2020). Trastuzumab Deruxtecan: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01281-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.